Loading data
STLANYSE
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 180.24 bn USD | 162.42 bn USD | 209.73 bn USD | 191.94 bn USD | 169.94 bn USD |
| Cost of revenue | 173.09 bn USD | 133.69 bn USD | 158.84 bn USD | 145.25 bn USD | 129.79 bn USD |
| Gross profit | 7.15 bn USD | 28.72 bn USD | 50.89 bn USD | 46.69 bn USD | 40.15 bn USD |
| Research and development expense | 13.09 bn USD | 5.99 bn USD | 6.21 bn USD | 5.56 bn USD | 5.1 bn USD |
| Selling, general and administrative expense | 23.28 bn USD | 15.62 bn USD | 16.8 bn USD | 15.16 bn USD | 15.49 bn USD |
| Operating profit after depreciation | -24.32 bn USD | 5.63 bn USD | 25.74 bn USD | 24.26 bn USD | 18.04 bn USD |
| Operating profit before depreciation | -16.13 bn USD | 13.11 bn USD | 34.08 bn USD | 31.53 bn USD | 24.66 bn USD |
| EBIT | -24.32 bn USD | 5.63 bn USD | 25.74 bn USD | 24.26 bn USD | 18.04 bn USD |
| EBITDA | -16.13 bn USD | 13.11 bn USD | 34.08 bn USD | 31.53 bn USD | 24.66 bn USD |
| Interest expense | 1.49 bn USD | 1.36 bn USD | 1.25 bn USD | 1.09 bn USD | 684 m USD |
| Profit before tax | -31.24 bn USD | 4.17 bn USD | 24.78 bn USD | 20.85 bn USD | 17.21 bn USD |
| Income tax expense | -5.02 bn USD | -1.54 bn USD | 4.19 bn USD | 2.92 bn USD | 2.17 bn USD |
| Income before extraordinary items | -26.26 bn USD | 5.67 bn USD | 20.56 bn USD | 17.95 bn USD | 15.02 bn USD |
| Net income (reported basis) | -26.26 bn USD | 5.67 bn USD | 20.56 bn USD | 17.95 bn USD | 16.15 bn USD |
| Basic EPS including extraordinary items | -9.1 USD/share | 1.93 USD/share | 6.61 USD/share | 5.72 USD/share | 5.28 USD/share |
| Diluted EPS including extraordinary items | -9.1 USD/share | 1.9 USD/share | 6.57 USD/share | 5.67 USD/share | 5.13 USD/share |
| Common dividends | 2.3 bn USD | 4.82 bn USD | 4.65 bn USD | 3.58 bn USD | 4.44 bn USD |
| Total dividends | 2.3 bn USD | 4.82 bn USD | 4.65 bn USD | 3.58 bn USD | 4.44 bn USD |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.